ArticleHealthcare (Basel, Switzerland)2022

What Do We Know So Far about Ofatumumab for Relapsing Multiple Sclerosis? A Meta-Analytical Study.

Hafiza Munazza Taj et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.